MGH/Harvard Study: Assessment of Glutamatergic Neurosystem in Fragile X Syndrome for Targeted Therapy

/, Research/MGH/Harvard Study: Assessment of Glutamatergic Neurosystem in Fragile X Syndrome for Targeted Therapy

MGH/Harvard Study: Assessment of Glutamatergic Neurosystem in Fragile X Syndrome for Targeted Therapy

MGH/Harvard is recruiting adult males with Fragile X syndrome, 18 years or older, for a neuroimaging study. Participants will be compensated up to $350.
 
The aim of the study is to examine problems with a chemical messenger called glutamate in the brain in Fragile X syndrome, and how it impacts sensory, motor and cognitive abilities and implicated structural and functional connectivity.
 
Three visits at Massachusetts General Hospital are required:
  • Medical history and behavioral testing (approx. 1.5 hours)
  • PET-MRI (approx. 2 hours)
  • Magnetoencephalography (approx. 1 hour).

The study started on March 15, 2018, and ends by June 30, 2020. The IRB approval number is 2017P001039.

Travel/time subsidy: compensation up to $350 for participation.

If you are interested, please contact:

Maria Mody, PhD
maria@nmr.mgh.harvard.edu
(617) 726-6913

If you arrived on this page through a MyFXResearch Portal search, you can close this window and return to your filtered results. Or start a new search here.
View More Opportunities

View All

Survey: Needs and Experiences of Families with Young Children with Fragile X

This survey will help support families in the Early Check study in NC whose newborns have been diagnosed with Fragile X and inform the design of an early intervention program for these babies.

Early Development of Young Children with Fragile X in North Carolina

RTI Int’l and UNC at Chapel Hill are conducting a research study to learn more about early development of young children with Fragile X in North Carolina, and the experiences of their parents when obtaining the diagnosis and early intervention services.

Metformin in Individuals with Fragile X Syndrome

We have preliminary evidence that metformin, a common type 2 diabetes medication, is beneficial for language, cognition, and behavior in both children and adults with Fragile X Syndrome.

Describing Anxiety for People with Fragile X Syndrome

A survey to measure levels of behavior. When someone with FXS is experiencing anxiety, describe what you see and hear, and how the experience impacts your/their quality of life.

Visual Perception Study

Our research is looking at how you see and remember the visual world, and how attention changes what we see. We hope our findings will provide a better understanding of the differences in vision and attention occurring in autism.

Purdue University: Brain and Behavior Study

Our goal is to better understand the different mechanisms within the brain that contribute to the development of psychiatric conditions, including depression, so we can establish better prevention and intervention efforts within this population.

By | 2019-07-16T15:18:29+00:00 Apr 5, 2018|Opportunities for families, Research|Comments Off on MGH/Harvard Study: Assessment of Glutamatergic Neurosystem in Fragile X Syndrome for Targeted Therapy